Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis

Indian Journal of Cancer

Volumn 33, Issue 1, 1996, Pages 17-20

  Parikh, Purvish M ^a   Shah, Samir R ^a   Shah, Sharad C ^a   Sheth, Vasant ^a   Patel, Rasik A ^a   Shah, Kishore C ^a   Jain, Pravin K ^a  

^a Sir Hurkisondas Nurrotumdas Hospital & Research Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; ONDANSETRON; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; PHYSIOLOGY; VOMITING;

ADULT; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; ONDANSETRON; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0030091166     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Schmoll H. J. : Introduction : The clinical challange. Eur J Cancer 1991:27; S1-S2.
2. Smyth J. F. : Preface. Eur J Cancer Clin Oncol. 1989 : 25; 83.
3. Parikh P.M., Charak B. S., Banavali S. D. et al : Prospective randomised double blind trial comparing metoclopramide alone with metoclopramide plus dexamethasone in prevention of high dose cisplatin induced emesis. Cancer 1988:62;2263-2266.
4. Schmoll H. J. : The role of ondansetron in the treatment of emesis induced by non-cisplatin containing chemotherapy regimes. Eur J Cancer Clin Oncol. 1989: 25;835-540.
5. Tyres M. B., Bunce K. T., Hymphrey P.P.A. : Pharmacological and anti-emetic properties of ondansetron. Eur J Cancer 1989 : 25; S15-S19.
6. Tonato M. : Ondansetron plus dexamethasone : An effective combination in high dose cisplatin therapy. Eur J Cancer 1991:27; S12-S14.